FDA wants more info on HGS anthrax drug

Human Genome Sciences (HGSI) says the FDA has denied its bid to gain an approval for its anthrax drug, asking for additional information on raxibacumab in a complete response letter. The delay is not a big surprise, given the recent vote by an advisory council to request more data on what benefits the drug provides beyond antibiotics. And the news hardly dented HGS stock in premarket trading; the company has been one of the hottest in the biotech sphere as investors thrilled to the news of the developer's progress with a new lupus drug. Report 

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.